About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Trial of SHR0302Base in Patients With Vitiligo | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingPhase 2NCT06790862

A Trial of SHR0302Base in Patients With Vitiligo

The purpose of this study is to evaluate the efficacy and safety of SHR0302Base in participants with nonsegmental vitiligo.

Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Sponsors

Lead Sponsor

Jiangsu HengRui Medicine Co., Ltd.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Clinically diagnosis of non-segmental vitiligo.
•2. The disease has been stable for more than 3 months (90 days) (stable disease is defined as no expansion of the original lesion and no new lesions).
•3. Subjects and their partners do not plan to have children, do not donate sperm/eggs, and voluntarily use highly effective contraception during the study period until 6 months (female subjects) or 3 months (male subjects) after dosing. Female subjects must have a negative serum pregnancy test and be non-lactating.

Exclusion Criteria

•1. Subjects diagnosed with segmental, mixed or undifferentiated vitiligo; Or previously diagnosed with other skin pigmentation disorders (except nevus halos).
•2. Conditions at baseline that would interfere with evaluation of vitiligo.
•3. Participants who have used skin bleaching treatments for past treatment of vitiligo or other pigmented areas.
•4. Use of protocol-defined treatments within the indicated washout period before baseline.

Related studies

RECRUITINGPhase 2

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

NCT07431177 · Non-segmental Vitiligo

RECRUITINGPhase 4

The Value of Methotrexate in NCES for Stable Vitiligo

NCT07352293 · Vitiligo

RECRUITINGPhase 4

Oral Mini Pulse Dexamethasone in Pediatric Vitiligo

NCT07353801 · Vitiligo

RECRUITINGPhase 2

Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo

NCT07437560 · NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)

RECRUITINGEARLY Phase 1

Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo

NCT07398807 · Vitiligo

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 15, 2026Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE2

Enrollment155

Start dateFeb 2025

Last updatedJan 15, 2026

Condition

Locations shown

Dermatology Hospital affiliated to Shandong First Medical University

Jinan, Shandong

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2026Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions